William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
Stocks · News reference
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Buy rating.